Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797275 | 1.00 | MAPT (0.44) | MAPTKDM4ECYP1A2ADRB2ADRB1 | |
| SCHEMBL6796958 | 1.00 | MAPT (0.44) | MAPTKDM4ECYP1A2ADRB2ADRB1 | |
| SCHEMBL6207040 | 0.85 | ALDH1A1 (0.38) | MAPTCYP1A2ADRB2ADRB1ADRB3 | |
| SCHEMBL18053153 | 0.84 | KDM4E (0.41) | MAPTKDM4ECYP1A2ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL6802704 | 0.83 | ALDH1A1 (0.37) | MAPTCYP1A2ADRB2ADRB1ADRB3 | |
| SCHEMBL18027695 | 0.81 | KDM4E (0.38) | MAPTKDM4ECYP1A2ADRB2ADRB1 | |
| SCHEMBL5014969 | 0.80 | SLC22A6 (0.41) | MAPTCYP1A2ADRB2ADRB1ADRB3 | |
| SCHEMBL16582259 | 0.80 | KDM4E (0.52) | MAPTKDM4EADRB2ADRB1CYP2D6 | |
| SCHEMBL30786011 | 0.79 | ALDH1A1 (0.50) | MAPTKDM4ECYP1A2ADRB2ADRB1 | |
| SCHEMBL6079267 | 0.78 | MGAM (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251470-A1 | ZWITTERIONIC POLYSACCHARIDE POLYMERS HAVING ANTIFOULING, ANTIMICROBIAL AND OPTICAL TRANSPARENCY PROPERTIES | NATIONAL SCIENCE FOUNDATION | 2016-09-01 | — | — | US | disclosed |
| US-20160244554-A1 | INTEGRATED ZWITTERIONIC CONJUGATED POLYMERS FOR BIOELECTRONICS, BIOSENSING, REGENERATIVE MEDICINE, AND ENERGY APPLICATIONS | THE UNIVERSITY OF AKRON | 2016-08-25 | — | — | US | disclosed |
| WO-2015057645-A9 | ZWITTERIONIC POLYSACCHARIDE POLYMERS HAVING ANTIFOULING, ANTIMICROBIAL AND OPTICAL TRANSPARENCY PROPERTIES | THE UNIVERSITY OF AKRON (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015057645-A1 | ZWITTERIONIC POLYSACCHARIDE POLYMERS HAVING ANTIFOULING, ANTIMICROBIAL AND OPTICAL TRANSPARENCY PROPERTIES | THE UNIVERSITY OF AKRON (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015054484-A1 | INTEGRATED ZWITTERIONIC CONJUGATED POLYMERS FOR BIOELECTRONICS, BIOSENSING, REGENERATIVE MEDICINE, AND ENERGY APPLICATIONS | THE UNIVERSITY OF AKRON (US) | 2015-04-16 | — | — | WO | disclosed |
| US-6740651-B2 | TREATING PARTICULARLY TUMORAL DISEASES, DISEASES OF THE LUNGS AND RESPIRATORY TRACT. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-05-25 | — | — | US | disclosed |
| US-20020115675-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115675-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K20, MAP3K19 | MAPT 4247/4885KDM4E 3299/4885CYP1A2 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.